Kohei Shitara, MD, on G-HOPE 001: Arcotatug Tavatecan in GI/GEJ Cancer

November 03, 2026

Kohei Shitara, MD, of the National Cancer Center Hospital East in Kashiwa, Japan, presents findings from the prespecified first interim analysis of the phase III G-HOPE 001 trial, which showed that arcotatug tavatecan, a CLDN18.2-targeted antibody-drug conjugate, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival with a manageable safety profile vs treatment of physician’s choice for patients with CLDN18.2-positive gastric or gastroesophageal junction (GEJ) cancer in the third-line and beyond setting (Abstract LBA77). 

Related Content